http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110179986-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
filingDate | 2019-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-110179986-B |
titleOfInvention | Medicine target for treating colon cancer |
abstract | The invention discloses a drug target for treating colon cancer, which is PTBP3 and HIF-1 alpha. The invention takes in vitro stable transfected cell lines or xenografts formed by the cell lines as research objects, and proves that the inhibition of HIF-1 alpha can enhance the treatment effect of PTBP3 on colon cancer through drug synergistic effect. The simultaneous inhibition of the two drug targets has obvious drug synergistic anti-tumor effect, and can be used as a novel treatment method for colon cancer. |
priorityDate | 2019-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 775.